• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hôpital Larrey,Centre Hospitalier Universitaire de Toulouse

    EST. 2000
    408论文总数
    4,426引用总数

    论文量&引用量时间轴

    机构学者

    排序
    A. Didier
    A. Didier
    service de pneumologie et allergologie, CHU de Toulouse
    论文:60引用:0H-index:0
    Julien Mazières
    Julien Mazières
    Université Paul Sabatier Toulouse III UFR PCA
    论文:42引用:0H-index:0
    Carle F Paul
    Carle F Paul
    Department of Dermatology, Toulouse University;Paul Sabatier University
    论文:25引用:0H-index:0
    Philippe Caron
    Philippe Caron
    Service d'Endocrinologie, Maladies Métaboliques et Nutrition, CHU de Toulouse
    论文:18引用:0H-index:0
    Prévot Grégoire
    Prévot Grégoire
    Service de pneumologie, Centre hospitalier universitaire de Toulouse
    论文:16引用:0H-index:0
    Laurent Brouchet
    Laurent Brouchet
    Serv Chirurg Thorac, CHU Toulouse
    论文:11引用:0H-index:0
    E. Serrano
    E. Serrano
    Dept ENT & Head & Neck Surg, Univ Hosp Toulouse
    论文:11引用:0H-index:0
    Juliette Mazereeuw-Hautier
    Juliette Mazereeuw-Hautier
    Centre Hospitalier Universitaire de Toulouse
    论文:11引用:0H-index:0
    Bruno Crestani
    Bruno Crestani
    Service de Pneumologie et Centre de Compétence des Maladies Pulmonaires Rares, Assistance Publique-Hôpitaux de Paris
    论文:10引用:0H-index:0

    论文(408)

    年份
    起
    –
    止
    排序
    1Efficacy and Safety of DANAZOL for Pulmonary Fibrosis or Bone-Marrow Failure Associated with Telomere-Related Gene Mutation
    Flore Sicre de Fontbrune,Stéphane Jouneau,Vincent Cottin,Grégoire Prevot,Hilario Nunes,Louis Terriou,Sylvain Marchand-Adam,Bruno Crestani,Ambroise Marcais,Anne Bergeron, Marie-Pierre Debray,Aurélie Plessier,

    Telomere-related gene (TRG) pathogenic variants are detected in ∼30% of familial pulmonary fibrosis (PF) cases. Danazol, a synthetic sex hormone with androgenic properties, has been found associated with telomere elongation and hematologic response in patients with short telomeres. The objective of the ANDROTELO multicenter, prospective, open-label single-arm phase II clinical trial ( NCT03710356 ) was to evaluate the efficacy and safety of danazol in carriers of TRG mutations with PF or bone-marrow failure (BMF).Included patients were carriers of a pathogenic or likely pathogenic TRG variant and presented a PF lung involving ≥10% parenchymal involvement on chest CT (PF group) and/or severe BMF (BMF group). Treatment was danazol 400 mg twice a day for 12 months. We included 25 patients with PF (16 males) and 5 with BMF (2 males). One PF patient withdrew consent. At inclusion, the median age in the PF group was 62.5 years, FVC 69% (interquartile range 40;120) and DLCO 44% (29;84). Ten of 24 PF patients (42%) completed the 12-month treatment. Causes of premature treatment discontinuation were side effects (n=9), death (n=3), lung transplantation (n=1), and disease progression (n=1). Fourteen PF patients were evaluated at month 12: 8 showed a relative decline of FVC of <5%. The median relative decrease in FVC and DLCO was −10% (interquartile range −14;−2) and −10.3% (−22.7;4.2). The 5 patients in the BMF group completed the 12-month treatment and exhibited at least partial response. Danazol was poorly tolerated in patients with TRG-related PF in this study, thus precluding efficacy assessment.

    2026ERJ open research(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Rapid Efficacy of Anifrolumab in Refractory Cutaneous Dermatomyositis.
    Chloé Grolleau,Thibault Mahévas, Pascale Daniel,Nicolas Schleinitz,Julien Seneschal,Marie-Sylvie Doutre,Christophe Richez,Aude Rigolet, Nicolas Champtiaux, Loraine Combemale, Vincent Langlois, Caroline Jacobzone-Leveque,
    2026Journal of the European Academy of Dermatology and Venereology JEADV(2026)
    引用
    AI阅读
    加入学术空间
    3Tolerance and Efficacy of Targeted Therapies after Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: the GFPC-TOXIMAD Study
    Thomas Pierret,Jean-Bernard Auliac,Charles Ricordel,Catherine Daniel, Jessica Nguyen,Florian Guisier,Aurélie Swalduz, Hubert Curcio, Anne Laure Desage, Laurence Bigay-Game,Eric Huchot,Lionel Falchero,

    Background: The sequential use of anti-programmed cell death (ligand)-1 [PD-(L)1] immune-checkpoint inhibitors (ICIs) followed by targeted tyrosine-kinase inhibitors (TKIs) for advanced non-small cell lung cancer (NSCLC) with oncogenic alterations raises questions about tolerance and efficacy. Recent study results suggested an increased risk of adverse events (AEs) with this sequence. Methods: Multicenter retrospective study on advanced NSCLC patients treated with ICIs followed by targeted therapies between 2015 and 2021. The primary endpoint was the rate of grade 3–5 adverse events (AEs). Main secondary endpoints were progression-free survival (PFS), time-to-treatment failure and overall survival (OS). Results: The analysis included 109 patients (most with EGFR, 30.3%; BRAF, 17.4%; MET exon-14, 17.4%; ALK, 10.1%; and RET, 6.4% gene alterations); 28/109, which is 25.7% of the patients, experienced grade 3/4 AEs and 4/109 (3.7%) experienced grade 5 AEs, leading to the definitive cessation of targeted therapy treatment in 14/32 (44%) of cases; higher grade 3–5 rates were observed with the dabrafenib–trametinib combination (12/16, 75%), capmatinib (4/8, 50%) and crizotinib (8/16, 50%). A last ICI-administration-to-targeted therapy-start interval of <90 days appeared to be associated with grade ≥ 3 AEs (32/82, 39% vs. 0/27 p = 0.001). In these sequential strategies, effectiveness of targeted therapies, in this second-line or later setting, appears to be lower than that in the published historical data. Conclusion: According to this analysis, sequential ICI–targeted therapy use for advanced NSCLC appeared to be associated with more grade 3–5 AEs.

    2026Current Oncology(2026)
    引用
    AI阅读
    加入学术空间
    4Chirurgia Di Riempimento Del Pectus Excavatum Con Impianti Su Misura Progettati Al Computer
    J.-P. Chavoin, B. Chaput, P. Leyx, B. Moreno,M. Dahan, J.-L. Grolleau

    Il pectus excavatum è di gran lunga la malformazione toracica congenita più frequente (90%). Le sue ripercussioni funzionali cardiopolmonari sono raramente all'origine della richiesta di correzione, che è il più delle volte motivata da ragioni estetiche e da un disagio sociale. La progettazione assistita da computer (CAD) si basa su una tomografia computerizzata (TC) toracica in sezioni sottili millimetriche. L'immagine digitale del riempimento anatomico perfetto, la prototipazione 3D, il modellamento e poi lo stampaggio del silicone e la sua polimerizzazione sono le fasi di una progettazione-fabbricazione assistita da computer (CAD/CAM). La procedura chirurgica è rapida (1 h), in un solo tempo e senza rischi: l'impianto è posizionato con precisione nella sua loggia profonda, sottopettorale cranialmente e sottoaponeurotico caudalmente sui muscoli retti dell'addome. La tecnica è efficace in tutte le forme asintomatiche, profonde o superficiali, asimmetriche, soprattutto nelle donne, e nelle forme basse con spina xifoidea (pectus arcuatum), molto frequenti e raramente citate in letteratura.

    2026EMC - Tecniche Chirurgiche - Chirurgia Plastica¸ Ricostruttiva ed Estetica(2026)
    引用
    AI阅读
    加入学术空间
    5Behavioural Changes in Exposure Patterns after Genetic Counselling among Asymptomatic First-Degree Relatives of Patients with Pulmonary Fibrosis and Carriers of a Telomere-Related Gene Variant.
    Lucile Sesé,Diane Bouvry,Caroline Kannengiesser,Lidwine Wémeau-Stervinou,Stephane Jouneau,Grégoire Prevot, Stephane Vagnarelli,Cécile Guérin, Albane Lassus,Bruno Crestani,Philippe Bonniaud,Vincent Cottin,

    While most relatives of TRG-variant carriers report exposure to inhaled toxics, few make behavioural changes within a year of genetic counselling https://bit.ly/4iEGBBN.

    2026ERJ open research(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 408 篇论文

    合作机构(100)

    巴黎医院公共援助合作论文 56
    Centre Hospitalier Universitaire de Toulouse合作论文 26
    里昂市民临终关怀院合作论文 25
    Hôpital Rangueil,Centre Hospitalier Universitaire de Toulouse合作论文 24
    Centre Hospitalier Régional et Universitaire de Lille合作论文 17
    University Hospital Medical Center at Treichville合作论文 17
    艾克斯 - 马赛大学合作论文 15
    Centre Hospitalier Universitaire de Bordeaux合作论文 15
    Hôpital Cochin,Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale,Assistance Publique – Hôpitaux de Paris合作论文 14
    古斯塔夫·鲁西研究所合作论文 14

    机构统计